Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Depreciation & Amortization (CF) (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Depreciation & Amortization (CF) for 5 consecutive years, with -$410000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 6.77% to -$410000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $197000.0, a 4.83% decrease, with the full-year FY2024 number at $197000.0, down 4.83% from a year prior.
  • Depreciation & Amortization (CF) was -$410000.0 for Q4 2024 at Actinium Pharmaceuticals, down from $202000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $221000.0 in Q3 2022 to a low of -$410000.0 in Q4 2024.
  • A 4-year average of $101687.5 and a median of $170500.0 in 2022 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): soared 66.17% in 2022, then tumbled 338.51% in 2023.
  • Actinium Pharmaceuticals' Depreciation & Amortization (CF) stood at $137000.0 in 2021, then rose by 17.52% to $161000.0 in 2022, then crashed by 338.51% to -$384000.0 in 2023, then fell by 6.77% to -$410000.0 in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Depreciation & Amortization (CF) are -$410000.0 (Q4 2024), $202000.0 (Q3 2024), and $189000.0 (Q2 2024).